| Identification | Back Directory | [Name]
BENZAMIDE, N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]-2-HYDROXY-3-IODO-6-METHOXY- | [CAS]
84226-06-2 | [Synonyms]
IBZM
S-(-)-IBZM
(s)-benzamid
3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
(s)-n-(1-ethyl-2-pyrrolidinyl)methyl-2-hydroxy-3-iodo-6-methoxybenzamide
BENZAMIDE, N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]-2-HYDROXY-3-IODO-6-METHOXY-
N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
IODOBENZAMIDE, (S)-(-)-3-IODO-2-HYDROXY-6-METHOXY-N[(1-ETHYL-2-PYRROLIDINYL)METHYL]BENZAMIDE | [Molecular Formula]
C15H21IN2O3 | [MDL Number]
MFCD00210201 | [MOL File]
84226-06-2.mol | [Molecular Weight]
404.24 |
| Hazard Information | Back Directory | [Chemical Properties]
Dark yellow oil | [Uses]
A halogenated benzamide derivative as potential radioligands for non-invasive quantification of D2-like dopamine receptor. The main purpose of a brain study with IBZM is the differentiation of Parkinson disease from other neurodegenerative disease | [Uses]
A halogenated benzamide derivative as potential radioligands for non-invasive quantification of D2-like dopamine receptor. The main purpose of a brain study with IBZM is the differentiation of Parkinson’s disease from other neurodegenerative diseases like Lewy Body dementia, multiple system atrophy. |
|
|